State Street’s Panbela Therapeutics, Inc. Common Stock PBLA Stock Holding History

State Street’s Portfolio PBLA Stock Details PBLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-89	Closed	-$23.5K	–	4835
2023 Q1	$23.5K	Buy	+89	New	+$86.3K	﹤0.01%	4663

Other funds holding PBLA

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

State Street's PBLA Position: Q2 2023 in Review

State Street sold out of Panbela Therapeutics, Inc. Common Stock (PBLA) in Q2 2023, closing a stake of 89 shares — an estimated $23.5K sold.

State Street first reported a position in PBLA in Q1 2023 and held it in 1 quarter. The position peaked at $23.5K in Q1 2023. 6 funds tracked by Wall St. Rank hold PBLA as of Q2 2023.

State Street reported no remaining Panbela Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
State Street sold 89 Panbela Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $23.5K.
State Street first reported a position in Panbela Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
State Street's Panbela Therapeutics, Inc. Common Stock position peaked at $23.5K in Q1 2023.
6 funds tracked by Wall St. Rank held Panbela Therapeutics, Inc. Common Stock as of Q2 2023.

Based on State Street's 13F filing for Q2 2023, filed 14 Aug 2023.